Navigation Links
Curemark LLC Reports Positive Phase III Results of CM-AT in Children With Autism
Date:12/7/2011

RYE, N.Y., Dec. 7, 2011 /PRNewswire/ -- Curemark LLC, a Rye, New York-based drug research and development company, today announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints.  The trial compared CM-AT to placebo in children with autism aged 3 – 8.  Top line results demonstrate a statistically significant effect of CM-AT over placebo on both core and non-core symptoms of autism.  Analysis of the full trial data is ongoing and the results will be presented at an upcoming medical meeting.

"We are extremely pleased with the results of our trial," said Dr. Joan Fallon, CEO of Curemark. "We wish to thank all the children and their parents who participated in the study, and look forward to a full review of the data by the FDA."

CM-AT has been granted Fast Track status by the Food and Drug Administration (FDA). The fast track programs of the Food and Drug Administration are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

About Curemark LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD.  In addition to CM-AT for autism, Curemark has two more drugs in development.  These are CM-4612 for Attention Deficit Hyperactivity Disorder (ADHD), for which the company has open Investigational New Drug (IND) clearance to conduct Phase III trials, and
'/>"/>

SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Curemark Issued Patent for the Diagnosis of Parkinsons Disease
2. Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity
3. Curemark Completes Enrollment of Phase III Autism Trials
4. Curemark Hosts New York Senator Kirsten Gillibrand
5. Curemark Appoints Jennifer Katritos, CPA as Vice President of Finance
6. Curemark Announces Four New Sites Participating in Autism Study
7. Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant
8. Curemark Moderates Autism Panel at Life Sciences Summit 2010
9. Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference
10. James F. Szigethy Named Curemarks Director of New Product Development
11. Curemark to Present at BioPharm America™ 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)...  An International Trade Commission (ITC) ruling issued Friday ... device, Taiwanese device manufacturer APEX continues to infringe ResMed ... ) is the innovation leader and pioneer in designing ... "Our research and development teams are ... of comfort, performance and efficacy," said David Pendarvis ...
(Date:7/21/2014)... Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... announces that the United States International Trade Commission (USITC) ... newly designed XT series continuous positive airway pressure (CPAP) ... the patent claims asserted by ResMed, one of Apex,s ... an upgraded iCH water tank to the market in ...
(Date:7/18/2014)... 2014 Hanger, Inc. (NYSE: HGR ) ... operations for the quarter ended June 30, 2014, on Tuesday, ... to discuss these results is scheduled to begin at 9:00 ... participate should call 1-877-662-6095. A replay will be available until ... ID # 44683027. About Hanger, Inc. – Built ...
Breaking Medicine Technology:ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2Apex Medical's Respiratory Therapy Product Receives Affirmation from USITC 2
... an international generic pharmaceuticals company, today announced that ... Food & Drug Administration to market Zolpidem Tartrate ... the product has commenced.   Actavis ... Extended-Release Tablets 6.25 mg strength in October 2010 with ...
... 6, 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ... the Phase IB/II study of the Btk inhibitor, PCI-32765, ... (CLL/SLL) at the 2011 American Society of Clinical Oncology ... development program update for the Btk Inhibitor, PCI-32765.  The ...
Cached Medicine Technology:Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S. 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 7Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 8Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 9
(Date:7/21/2014)... July 21, 2014 What do romance, ... have in common? You can find them all in ... novel's main character, Miranda, lives on Martha’s Vineyard with ... a wealthy New Yorker, and becomes entangled in a ... Heart challenges readers to think about what choices they ...
(Date:7/21/2014)... (Philadelphia, PA) Patients who have a clot ... be treated with traditional blood-thinning medication or undergo ... comfortable that there is no difference in death ... more bleeding risks with the catheter procedure, according ... Medicine researchers. The study involved a review of ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Executives ... agency specializing in private healthcare practices, will participate ... (IACA). They will be showcasing their state-of-the-art capabilities ... medical practices all over the United States as ... efforts continues to increase. Advice Media’s presence at ...
(Date:7/21/2014)... MONDAY, July 21, 2014 (HealthDay News) -- The "viral ... avoiding detection and elimination, is established much earlier than ... poses new obstacles for those working to eradicate the ... Military HIV Research Program. They said the presence of ... finding a cure for a subtype of HIV, known ...
(Date:7/21/2014)... Public Affairs Research has released the results of a ... means to be a quality health care provider in ... Wood Johnson Foundation, sheds new light on how American ... doctors, as well as the information they use and ... new and actionable data during a crucial period of ...
Breaking Medicine News(10 mins):Health News:Thea Marsh Releases Debut Novel that Celebrates and Reaches out to Women Everywhere 2Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4Health News:Advice Media to Attend the International Association of Comprehensive Aesthetics Conference (IACA) Targeting the Dental Profession 2Health News:Animal Experiments Shed Light on HIV's Ability to Hide 2Health News:National survey from AP-NORC examines perceptions of health care provider quality 2
... Central government and striking medicos to end the agitation ... Castes// in educational institutes failed to reach any conclusion ... decision to implement the 27% reservation for OBCs in ... that they would plan to make their agitation 'more ...
... to a study it was found that a number ... measures, like a daily dose of aspirin, colon cancer ... young women, immunizing adults against the flu and pneumonia ... longer and healthier lives. The study’s results were published ...
... Ranbaxy Laboratories Limited today entered into an in-licensing agreement ... (NDDS) analgesic // , Tramadol in the Indian market ... the wholly-owned subsidiary of the French drug major for ... ,The product will be supplied from Ethypharm's manufacturing ...
... Laboratories Limited today said the World Health Organistion has ... products in its pre-qualification list. // ,The ... 200mg capsules, Stavudine 30mg capsules, Stavudine 40mg capsules, the ... significant development. We strongly feel that Generic ARVs are ...
... aroused as fear about childhood obesity grows and thus ... ... child-sized machines, during the past two years. ... Shokk and Zig Zag was building new facilities and installing machines for their little customers. ,According to ...
... Cabinet today cleared the business model for the state-of-the-art Institute ... the capital. // ,The model approved by the ... would enable the institute to be self-sufficient in nine years' ... the finances for procuring medical equipment would be borne by ...
Cached Medicine News:Health News:Disappointed Students Plan To Intensify Agitation Nationwide 2
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: